Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma-Reference-Cited by-同舟云学术

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

Published:2013-07-16 Issue:3 Volume:109 Page:552-558
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ceresoli G L,Zucali P A,Mencoboni M,Botta M,Grossi F,Cortinovis D,Zilembo N,Ripa C,Tiseo M,Favaretto A G,Soto-Parra H,De Vincenzo F,Bruzzone A,Lorenzi E,Gianoncelli L,Ercoli B,Giordano L,Santoro A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013368.pdf

Reference37 articles.

1. Abu-Hejleh T, Mezhir JJ, Goodheart JJ, Halfdanarson TR (2012) Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14: 277–284.

2. Baas P, Buikhuisen W, Dalesio O, Vincent A, Pavlakis N, Van Klaveren R, Schramel F, Custers F, Schouwink H, Burgers SA (2011) A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J Clin Oncol 29 (suppl): abstr 7006.

3. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257–260.

4. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical application of angiogenesis. Nature 473: 298–307.

5. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella R, Mencoboni M (2008) Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19: 370–373.

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022;Journal of Neuro-Oncology;2024-06-29

2. Recent Advances in Mesothelioma;Current Pulmonology Reports;2024-05-23

3. Mesothelioma: Pleural, Version 1.2024;Journal of the National Comprehensive Cancer Network;2024-03

4. A rare malignant mesothelioma of the tunica vaginalis testis: A case report;Oncology Letters;2024-02-23

5. The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review;Journal of Thoracic Disease;2024-01